Innovative developments and emerging technologies in RNA therapeutics. Issue 1 (31st December 2022)

• Record Type: Journal Article
• Authors: Halloy, François; Biscans, Annabelle; Bujold, Katherine E.; Debacker, Alexandre; Hill, Alyssa C.; Lacroix, Aurélie; Luige, Olivia; Strömberg, Roger; Sundstrom, Linda; Vogel, Jörg; Ghidini, Alice
• Is Part Of: RNA biology. Volume 19:Issue 1(2022)
• Page Start: 313
• Page End: 332
• Publication Date: 2022-12-31
• Subjects: RNA-therapeutics -- antisense -- siRNA -- delivery -- saRNA -- nucleic acid technologies -- viral RNA -- oligonucleotide based artificial ribonucleases -- PROTAC; RNA -- Periodicals; Molecular biology -- Periodicals; Molecular biology; RNA; Periodicals; 572.8805
• DOI: 10.1080/15476286.2022.2027150
• Languages: English
• ISSNs: 1547-6286

Abstract

ABSTRACT: RNA-based therapeutics are emerging as a powerful platform for the treatment of multiple diseases. Currently, the two main categories of nucleic acid therapeutics, antisense oligonucleotides and small interfering RNAs (siRNAs), achieve their therapeutic effect through either gene silencing, splicing modulation or microRNA binding, giving rise to versatile options to target pathogenic gene expression patterns. Moreover, ongoing research seeks to expand the scope of RNA-based drugs to include more complex nucleic acid templates, such as messenger RNA, as exemplified by the first approved mRNA-based vaccine in 2020. The increasing number of approved sequences and ongoing clinical trials has attracted considerable interest in the chemical development of oligonucleotides and nucleic acids as drugs, especially since the FDA approval of the first siRNA drug in 2018. As a result, a variety of innovative approaches is emerging, highlighting the potential of RNA as one of the most prominent therapeutic tools in the drug design and development pipeline. This review seeks to provide a comprehensive summary of current efforts in academia and industry aimed at fully realizing the potential of RNA-based therapeutics. Towards this, we introduce established and emerging RNA-based technologies, with a focus on their potential as biosensors and therapeutics. We then describe their mechanisms of action and their application in different disease contexts, along with the strengths and limitations of each strategy. Since the nucleic acid toolbox is rapidly expanding, we also introduce RNA minimal architectures, RNA/protein cleavers and viral RNA as promising modalities for new therapeutics and discuss future directions for the field.